<DOC>
	<DOCNO>NCT01021813</DOCNO>
	<brief_summary>This study establish safety tolerability suvorexant ( MK-4305 ) administer 14 month . Participants randomize receive suvorexant placebo 12-month double-blind ( DB ) Treatment Phase . Participants complete 12-month DB Treatment Phase enter 2-month DB Randomized Discontinuation Phase . At time initial randomization , participant assign receive suvorexant initial 12-month Treatment Phase simultaneously randomize , 1:1 ratio , receive either suvorexant placebo 2-month Randomized Discontinuation Phase . Participants randomize receive placebo initial 12-month Treatment Phase continue receive placebo 2-month Randomized Discontinuation Phase . The first 3 night Randomized Discontinuation Phase refer Run-Out Phase , ass rebound withdrawal .</brief_summary>
	<brief_title>A Long Term Safety Study Suvorexant Participants With Primary Insomnia ( MK-4305-009 AM3 )</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Suvorexant</mesh_term>
	<criteria>Diagnosis primary insomnia Participant able read , understand , complete questionnaire diary If female , participant partner agree use acceptable contraception . If male partner use effective form contraception , female participant must use 2 acceptable form contraception If ≥65 year age , score ≥25 Mini Mental State Examination ( MMSE ) If female , participant pregnant Participant expect donate egg sperm study Recent and/or active history confound neurological disorder History clinically unstable cardiovascular disorder within last 6 month Lifetime history bipolar disorder Psychiatric condition require treatment medication prohibit study , psychiatric condition would interfere participant 's ability participate study History substance abuse/dependence History cancer ≤5 year prior study participation except adequately treat basal cell squamous cell skin cancer situ cervical cancer Evidence suicidality ( base score 2 Quick Inventory Depressive Symptomatology SelfReport 16Item ( [ QIDSSR16 ] suicide item # 12 ) Participant travel across &gt; 3 time zone &gt; 3 hour time difference last 2 week History permanent night shift work rotate day/night shift work past 2 week Body Mass Index ( BMI ) &gt; 40 kg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>